Clinical Trial

Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)

• Provides Protection Through Sept. 2044; Will Be Listed in FDA’s Orange Book CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE)...

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Additional complete response (CR) observed in patient with multiple tumorsConfirmed overall response rate (ORR) of 50% in patients with combined...

Cognition Therapeutics’ Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

- Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive...

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

CELEBRATION, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company...

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant...

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

-- Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- --...

Immorta Bio, a Scientific Longevity Company, Appoints Pharmaceutical Industry Veteran Dr. Armin Rath as Chief Business Officer

Senolytic Immunotherapy Leader Expands Executive Team in Anticipation of Clinical Trial Launch MIAMI BEACH, Fla., July 15, 2025 /PRNewswire/ --...

Predictive Oncology Issues Shareholder Letter: Well Financed to Support Expanded U.S. Availability and E.U. Launch of ChemoFx® and Pursuit of Other High-Value AI-Driven Drug Discovery and Development Opportunities

$10 million securities purchase agreement provides efficient and flexible funding in support of strategic multi-million dollar growth initiatives Discussions underway...

Flatiron Health Research on AI-Driven Cancer Progression Extraction Presented at AACR Special Conference in Cancer Research: Artificial Intelligence and Machine Learning 2025

Flatiron Health presents two new pieces of research demonstrating the potential of AI to advance oncology research across multiple tumor...

error: Content is protected !!